NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Janux Therapeutics, Inc. (JANX) Stock Analysis

Janux Therapeutics, Inc. (JANX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

JANX

$20.24

+$0.44 (+2.22%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare JANX with… →

JANX Key Statistics

As of Sep 4, 2026
Trading
Open
$19.62
Previous Close
$19.80
Day's Range
19.57–20.31
52-Week Range
12.12–35.34
Volume
700.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.52
Valuation
Market Cap
$1.24B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
51.56
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.64
Financials (FY)
Revenue (FY)
$10.00M−5.55%
Net Income (FY)
−$113.63M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
61.14M
1-Year Return
−15.46%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
1.02M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

JANX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+46.67%
2025−74.22%
2024+398.97%
2023−18.53%
2022−33.25%
2021 (partial year)−21.55%

As of September 4, 2026.

JANX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$10.00M−$113.63M−1136.3%
2024$10.59M−$68.99M−651.6%
2023$8.08M−$58.29M−721.2%
2022$8.61M−$63.06M−732.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$10.00M—−$157.67M−$113.63M−1136.3%
2024$10.59M—−$98.85M−$68.99M−651.6%
2023$8.08M—−$72.98M−$58.29M−721.2%
2022$8.61M—−$67.09M−$63.06M−732.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

JANX Valuation vs Biotechnology Median

Median of 656 stocks
MetricJANXBiotechnology medianvs median
P/S ratio51.5615.263.4x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Janux Therapeutics, Inc. (JANX) carries a market capitalisation of $1.24B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 113.

Over the past 52 weeks the price has ranged from $12.12 to $35.34. JANX last closed at $20.24 on September 4, 2026. That is +$0.44 (+2.22%) against the previous close. The latest close sits 67% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $10.00M. Against the prior fiscal year total of $10.59M, that is a change of −5.55%. The same year closed with a net loss of $113.63M. The reported profit margin is 0%. Trailing earnings per share are −1.64.

Across the 4 fiscal years on file, revenue moves from $8.61M in 2022 to $10.00M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 51.56 times revenue. On price-to-sales that is 3.4 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −15.46%. Measured over 5 years, that is −8.34% a year compounded. The reported beta is 2.52. Annualized volatility over the trailing 5 years is 130.27%.

Growth & Income

The record shows no dividend for JANX.

2026 is still running; the price is +46.67% year to date. The strongest complete calendar year on file is 2024 at +398.97%; the weakest is 2025 at −74.22%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

Janux Therapeutics, Inc. (JANX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Janux Therapeutics, Inc. JANX $1.24B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Janux Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Janux Therapeutics, Inc.

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Visit website →